StockpollyBeta
Get App
Popularity #3,952
GANX · NASDAQ · Biotechnology

Gain Therapeutics (GANX)

Develops allosteric medicines and rexaceract for Parkinson’s disease.

$1.86
vs last close−0.10 (−4.87%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
544843455455
Research & development223431233232
322422222233
General & administrative322422222233
Operating income−5−4−4−8−4−3−4−5−5−4−5−5
0000000−10000
Interest income000000000000
Other non-operating income000000010000
Income before tax−5−5−4−8−4−3−4−6−5−4−5−5
Income tax expense000001001000
Net income from continuing operations−5−5−4−8−4−4−5−6−5−5−6−5
Net income−5−5−4−8−4−4−5−6−5−5−6−5
EPS, basic−$0.37−$0.29−$0.22−$0.42−$0.17−$0.14−$0.16−$0.19−$0.15−$0.11−$0.13−$0.11
EPS, diluted−$0.37−$0.29−$0.22−$0.42−$0.17−$0.14−$0.16−$0.19−$0.15−$0.11−$0.13−$0.11
Weighted average shares, basic131618192727293035334243
Weighted average shares, diluted131618192727293035334243
EBITDA−5−5−4−8−4−3−4−6−5−4−5−5
Depreciation & amortization000000000000
EBIT−5−5−4−8−4−3−4−6−5−4−5−5